36th week of 2014 patent applcation highlights part 36 |
Patent application number | Title | Published |
20140249018 | GLASS SUBSTRATE FOR FLAT PANEL DISPLAY AND MANUFACTURING METHOD THEREOF - A flat panel display glass substrate according to the present invention includes a glass comprising, as expressed in mol %, 55-80% SiO | 2014-09-04 |
20140249019 | GLASS SUBSTRATE FOR FLAT PANEL DISPLAY AND MANUFACTURING METHOD THEREOF - A glass substrate for p-Si TFT flat panel displays that is composed of a glass comprising 52-78 mass % of SiO | 2014-09-04 |
20140249020 | CERAMIC BODY FORMING BATCH MATERIALS COMPRISING SILICA METHODS USING THE SAME AND CERAMIC BODIES MADE THEREFROM - The disclosure relates to ceramic-body-forming batch materials comprising at least one pore former and inorganic batch components comprising at least one silica source having a specified particle size distribution, methods of making ceramic bodies using the same, and ceramic bodies made in accordance with said methods. The disclosure additionally relates to methods for reducing pore size variability in ceramic bodies and/or reducing process variability in making ceramic bodies. | 2014-09-04 |
20140249021 | WET CHEMICAL AND PLASMA METHODS OF FORMING STABLE PTPD CATALYSTS - A nano-particle comprising: an interior region comprising a mixed-metal oxide; and an exterior surface comprising a pure metal. In some embodiments, the mixed-metal oxide comprises aluminum oxide and a metallic pinning agent, such as palladium, copper, molybdenum, or cobalt. In some embodiments, the pure metal at the exterior surface is the same as the metallic pinning agent in the mixed-metal oxide in the interior region. In some embodiments, a catalytic nano-particle is bonded to the pure metal at the exterior surface. In some embodiments, the interior region and the exterior surface are formed using a plasma gun. In some embodiments, the interior region and the exterior surface are formed using a wet chemistry process. In some embodiments, the catalytic nano-particle is bonded to the pure metal using a plasma gun. In some embodiments, the catalytic nano-particle is bonded to the pure metal using a wet chemistry process. | 2014-09-04 |
20140249022 | REDUCED FLUIDIZATION OF SOLID PARTICLES IN RADIAL FLOW FLUID/SOLID CONTACTING - Apparatuses and methods are disclosed for contacting radially flowing fluids with solid particles (e.g., catalyst) with reduced tendency for fluidization of the particles, and especially a sealing portion of the particles at the top of a particle retention zone disposed between screens at upstream and downstream positions relative to radial fluid flow. Fluidization is reduced or eliminated by offsetting openings of the screens in the axial direction, such that upstream openings in the upstream screen are above highest downstream openings in a downstream stream. The offset in openings imparts a downward flow component to radially flowing fluid, thereby reducing solid particle fluidization without the need to induce a specific pressure drop profile along the entire axial direction of the screens. | 2014-09-04 |
20140249023 | ADSORBENT COMPOSITION FOR ARGON PURIFICATION - An optimal material composition that allows for the purification of at least one feed component from a fluid feed stream such that the adsorbent has an oxygen capacity of at least 10 weight percent is described. More specifically, the material is an adsorbent for purification of a fluid feed stream having an oxygen to argon selectivity greater than or equal to a ratio of 3:1 and an oxygen capacity of greater than or equal to 10 weight percent, wherein the oxygen capacity is measured at a pressure in the range of about 9-10 Torr and a temperature of 77 degrees Kelvin after 4 hours of equilibration time and wherein the oxygen to argon selectivity is obtained by dividing the oxygen capacity by the argon capacity of the adsorbent measured at a pressure in the range of about 697-700 Torr and a temperature of 87 degrees Kelvin after 8 hours of equilibration time. The adsorption capacities are measured on a pure component basis. | 2014-09-04 |
20140249024 | Pesticidal Methods Using Substituted 3-pyridyl Thiazole Compounds and Derivatives for Combating Animal Pests II - The present invention relates to pesticidal methods for the use and application of substituted 3-pyridyl thiazole compounds and the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising the same. The invention also relates to insecticidal substituted 3-pyridyl thiazole compounds or of the compositions comprising such compounds for combating invertebrate pests and uses thereof. | 2014-09-04 |
20140249025 | 1,3-DIARYL-SUBSTITUTED HETEROCYCLIC PESTICIDES - Disclosed are compounds of Formula 1, N-oxides, and salts thereof, | 2014-09-04 |
20140249026 | GLYPHOSATE COMPOSITION FOR DICAMBA TANK MIXTURES WITH IMPROVED VOLATILITY - Herbicidal concentrate compositions containing glyphosate salts and tank mix compositions containing a combination of glyphosate salt and dicamba salt herbicides are described. A method of preparing a tank mix composition comprising a glyphosate component and a dicamba component is also described. The method includes combining a glyphosate concentrate composition, a dicamba composition comprising one or more salts of dicamba and dilution water to form the tank mix composition. The glyphosate concentrate composition comprises a glyphosate salt selected from the group consisting of the monoethanolamine salt, the potassium salt, and mixtures thereof at a glyphosate loading of at least about 240 grams acid equivalent per liter (g a.e./l), and the pH of a 5 wt. % acid equivalent dilution of the glyphosate concentrate composition is from about 5 to about 6.5. | 2014-09-04 |
20140249027 | NOVEL GLYPHOSATE-N-ACETYLTRANSFERASE (GAT) GENES - Novel proteins are provided herein, including proteins capable of catalyzing the acetylation of glyphosate and other structurally related proteins. Also provided are novel polynucleotides capable of encoding these proteins, compositions that include one or more of these novel proteins and/or polynucleotides, recombinant cells and transgenic plants comprising these novel compounds, diversification methods involving the novel compounds, and methods of using the compounds. Some of the novel methods and compounds provided herein can be used to render an organism, such as a plant, resistant to glyphosate. | 2014-09-04 |
20140249028 | HERBICIDAL COMPOSITIONS AND METHOD OF USE THEREOF - An emulsifiable concentrate herbicidal composition that contains Prodiamine herbicide and fenoxaprop-p-ethyl that shows excellent spreadability and stability and is particularly suitable for effective control of weeds in general residential and commercial landscaped areas. | 2014-09-04 |
20140249029 | Solid Agricultural Compositions - Suggested are solid agricultural compositions, comprising: (a1) at least one alkoxylated alcohol according to general formula (I) R | 2014-09-04 |
20140249030 | STABLE AND NON-PRECIPITATING AQUEOUS COMPOSITIONS CONTAINING THE POTASSIUM SALT OF (S)-(+)-ABSCISIC ACID, AND METHODS OF THEIR PREPARATION AND USE - The present invention generally relates to aqueous compositions containing salts of (S)-(+)-abscisic acid, the surfactant Atlox™ 4913, and the color stabilizers sodium citrate and sodium acetate, methods of their preparation, and methods of their agricultural use. | 2014-09-04 |
20140249031 | MICELLE-COATED CRYSTALLINE PARTICLES - The present invention relates to crystalline particles [particularly organic particles or agrochemical particles] coated with micelles of copolymers, to compositions comprising such particles, to a process for preparing the coated particles and to uses of the particles and the compositions [for example to produce surface coatings with high loadings of copolymer and uses of products derived therefrom]. | 2014-09-04 |
20140249032 | Crop Oil Concentrate Adjuvants Containing Amine Surfactants - In agricultural practice it is known to use emulsifiable oils (commonly referred to a Crop Oil Concentrates, COC) as bioefficacy enhancers for pesticides, especially herbicides. Cationic surfactants are widely known to be particularly effective bio-active enhancers for herbicides, especially for glyphosate-type herbicides. The present invention includes two novel aspects: 1) While the vast majority of COCs are petroleum-based paraffinic oils or esterified seed oils, this invention embodies a new oil phase, a hydrocarbon oil such exemplified by EXXON-MOBIL'S D-130, which when combined with the surfactants described herein, exhibits surprising enhancement of herbicidal activity in field tests; and 2) COC's are designed to form stable emulsions in water. The combination of cationic surfactants and phosphate esters in this invention not only form very stable emulsions in water, but, surprisingly, also form extremely stable emulsions in concentrated liquid fertilizers, including 32-0-0 fertilizer. | 2014-09-04 |
20140249033 | DC SQUID BASED RF MAGNETOMETER OPERATING AT A BANDWIDTH OF 200 MHZ AND HIGHER - An RF DC SQUID based magnetometer capable of sensing coherent magnetic fields up to 200 MHz and higher is developed which overcomes frequency limitations associated with noise signals due to transmission line delays between the SQUID circuit and readout electronics. The bandwidth limitations are overcome by superimposing the RF flux on the modulation flux to produce at the SQUID output a binary phase modulated RF voltage, which is processed to lock the static flux, and to control modulation regime by producing an AC bias for the RF flux. RF readout electronics based on a double lock-in technique (sequential demodulation of the RF SQUID voltage at the modulation flux frequency ω | 2014-09-04 |
20140249034 | SUPERCONDUCTING ELEMENT FOR SUPERCONDUCTING FAULT CURRENT LIMITER, METHOD FOR MANUFACTURING SUPERCONDUCTING ELEMENT FOR SUPERCONDUCTING FAULT CURRENT LIMITER, AND SUPERCONDUCTING FAULT CURRENT LIMITER - A superconducting element for a superconducting fault current limiter, including a substrate | 2014-09-04 |
20140249035 | METHODS, SYSTEMS, AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIO-MOLECULES - The present invention generally relates to methods of rapidly and efficiently searching biologically-related data space. More specifically, the invention includes methods of identifying bio-molecules with desired properties, or which are most suitable for acquiring such properties, from complex bio-molecule libraries or sets of such libraries. The invention also provides methods of modeling sequence-activity relationships. As many of the methods are computer-implemented, the invention additionally provides digital systems and software for performing these methods. | 2014-09-04 |
20140249036 | METHOD AND KIT FOR CHARACTERIZING MICROORGANISMS - The present disclosure provides methods of characterizing one or more microorganisms and kits for characterizing at least one microorganism. Exemplary methods include preparing an amplicon library, sequencing a characteristic gene sequence to obtain a gene sequence, and characterizing the one or more microorganisms based on the gene sequence using a computer-based genomic analysis of the gene sequence. Exemplary kits include at least one forward primer including an adapter sequence and a priming sequence, for a target sequence, and at least one reverse primer. | 2014-09-04 |
20140249037 | METHOD AND KIT FOR CHARACTERIZING MICROORGANISMS - The present disclosure provides methods of characterizing one or more microorganisms and kits for characterizing at least one microorganism. Exemplary methods include preparing an amplicon library, sequencing a characteristic gene sequence to obtain a gene sequence, and characterizing the one or more microorganisms based on the gene sequence using a computer-based genomic analysis of the gene sequence. Exemplary kits include at least one forward primer including an adapter sequence and a priming sequence, for a target sequence, and at least one reverse primer. | 2014-09-04 |
20140249038 | Method of detecting a pre-determined event in a nucleic acid sample and system thereof - Disclosed are a method of detecting a pre-determined event in a nucleic acid sample and a system thereof. The method of detecting the pre-determined event in the nucleic acid sample comprises the following steps: constructing a sequencing-library for the nucleic acid sample; sequencing the sequencing-library to obtain a sequencing result consisting of a plurality of sequencing data; determining the sequencing data from a pre-determined region; and determining an occurrence of the pre-determined event in the nucleic acid sample based on a composition of the sequencing data from the pre-determined region. | 2014-09-04 |
20140249039 | METHODS OF MACROMOLECULAR ANALYSIS USING NANOCHANNEL ARRAYS - Methods of analyzing features such as the physical size of macromolecules or biomarkers along large genomic DNA molecules were disclosed as wen as the devices for carrying out such high throughput analysis in a massively parallel fashion. Methods of fabricating such devices are also disclosed. | 2014-09-04 |
20140249040 | ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS - Disclosed is a method for in situ detection of one or more target nucleic acids based on a combination of RNAscope® method and a general ISH signal amplification method. This new method produces high signal intensity and while keeps low background noise of signal amplification. The result can be consistently reproduced and the method can be easily adopted for routine clinic diagnostic use. Further, the invention relates to a kit, comprising the components of RNAscope® assay and a general ISH signal amplification assay, for sensitive detection of one or more target nucleic acids. | 2014-09-04 |
20140249041 | Marker of Prostate Cancer - An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods. | 2014-09-04 |
20140249042 | DETECTION OF BIOAGENTS USING A SHEAR HORIZONTAL SURFACE ACOUSTIC WAVE BIOSENSOR - Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×10 | 2014-09-04 |
20140249043 | Multiplexed Analyses of Test Samples - The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications. | 2014-09-04 |
20140249044 | Cell-Based Methods for Coupling Protein Interactions and Binding Molecule Selection and Diversification - The invention relates to cell-based methods for diversifying, expressing and selecting binding molecules, e.g., antibodies, and target molecules to which they bind, all of which are expressed in the same cell. The target molecule can be a member of a ligand binding pair comprising a cell-surface expressed ligand binding receptor molecule and its cognate ligand, which interact within the cell. The methods provide retaining either the antibody or its target in a cell organelle as the site of binding and interaction. By performance of the methods, the binding or non-binding of the antibody to its target molecule within the cell produces a cell phenotype that is detectable at the cell surface via high throughput assays, e.g., flow cytometry. The methods are particularly useful for generating, recovering and providing antibodies that have optimal target molecule binding properties or activities for potential therapeutic use. Methods for generating diversity in such antibodies are also provided. | 2014-09-04 |
20140249045 | NOVEL USE OF LEUCYL TRNA SYNTHETASE - Provided is a method of screening for agents for preventing or treating mTORC1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells. | 2014-09-04 |
20140249046 | SSR MARKERS FOR PLANTS AND USES THEREOF - Simple sequence repeat (SSR) markers identified in | 2014-09-04 |
20140249047 | GENETIC MARKER FOR THE DIAGNOSIS OF DEMENTIA WITH LEWY BODIES - Specific polymorphisms in BChE gene have been found which allow determining whether a patient suffers from dementia with Lewy bodies (DLB), and allow distinguishing it from Alzheimer's disease. The invention provides an in vitro method for the diagnosis of DLB comprising determining in a biological sample from a subject, the genotype of the following polymorphisms in butyrylcholinesterase (BChE) gene: the polymorphic site at position 3687 in NCBI Accession Number NG_009031 (i.e. SEQ ID NO: 1) the polymorphic site at position 4206 in SEQ ID NO: 1, the polymorphic site at position 4443 in SEQ ID NO: 1. and the polymorphic site at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 26). | 2014-09-04 |
20140249048 | Novel Prostate Kallikrein Allergen - Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient. | 2014-09-04 |
20140249049 | USE OF CD5 ANTIGEN-LIKE AS A BIOMARKER FOR DIABETIC NEPHROPATHY - Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV. | 2014-09-04 |
20140249050 | METHOD AND DEVICE FOR THE MANIPULATION OF MICROCARRIERS FOR AN IDENTIFICATION PURPOSE - Disclosed is a method for the manipulation for an identification purpose of a microcarrier comprising the steps of: (a) an identification purpose step of the microcarrier; and (b) a positioning and orientation step prior to or during the identification purpose step. Also disclosed is an apparatus for the manipulation for identification purposes of a microcarrier comprising means for identification purposes such as a microscope or labelling means such as a high spatial resolution light source, and means for the positioning and orientation of the microcarriers. | 2014-09-04 |
20140249051 | METHOD AND SYSTEM FOR ABO ANTIBODY DETECTION AND CHARACTERIZATION - The present application discloses a system and method for ABO antibody detection and characterization that can provide an alternative means for assessment and management of ABO-incompatible and ABO-compatible transplants. The method and system comprises determining an anti-ABO blood group antigen subtype antibody profile of a subject using a biological sample from the subject. The method and system can be used to evaluate the suitability of a donor blood or tissue product for a recipient subject by comparing the determined anti-ABO antigen subtype antibody profile of the recipient subject with the ABO histo-blood group or ABO histo-blood subgroup of a donor blood or tissue product. In order to define the subject's ABO histo-blood subgroup, the determined antibody profile is compared to known ABO histo-blood group antigen subtype profiles and/or known anti-ABO antigen subtype antibody profiles for ABO histo-blood subgroups to identify the ABO histo-blood subgroup of the subject. Profiles can be established by applying a sample to an array of surface-bound ABO antigens selected from the group of type I to type VI antigens of each blood group A, B or H. | 2014-09-04 |
20140249052 | Polypeptides and their use - The present invention provides polypeptides that bind to inorganic solid surfaces, structures comprising such polypeptides, and methods of making such structures. | 2014-09-04 |
20140249053 | NANOPARTICLE PROBES, METHODS, AND SYSTEMS FOR USE THEREOF - Methods of identifying geological materials of interest comprising (i) providing a nanoprobe composition comprising one or more nanoprobes; wherein the nanoprobe includes (a) at least one tag; and (b) at least one signal generator; (ii) introducing the nanoprobes to a geological material; and (iii) detecting the presence of a signal generated by the signal generator on association of the tag with a target. Nanoprobe compositions identify geological materials, systems include such nanoprobe compositions, and methods use such nanoprobe compositions for the evaluation of geological materials. | 2014-09-04 |
20140249054 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS - Multiplex enzyme assay methods and compositions for simultaneously assaying the activities of a plurality of lysosomal enzymes. | 2014-09-04 |
20140249055 | SYSTEMS AND METHODS FOR SELF-REFERENCED DETECTION AND IMAGING OF SAMPLE ARRAYS - A system for detecting an array of samples having detectable samples and at least one reference sample is provided. The system comprises an electromagnetic radiation source, a sensing surface comprising a plurality of sample fields, wherein the plurality of sample fields comprise at least one reference field, a phase difference generator configured to introduce differences in pathlengths of one or more samples in the array of samples, and an imaging spectrometer configured to image one or more samples in the array of samples. | 2014-09-04 |
20140249056 | BILAYERS - A method for producing a bilayer, the method comprising: (a) providing a hydrated support and a hydrophilic body immersed in a hydrophobic medium; wherein a first monolayer of amphipathic molecules is formed on an interface between the hydrophobic medium and the hydrophilic body and a second monolayer of amphipathic molecules is formed on an interface between the hydrophobic medium and the hydrated support; and (b) bringing the first monolayer into contact with the second monolayer to form a bilayer of amphipathic molecules, wherein at least part of a cell membrane, comprising cell membrane constituents, is provided in or on the hydrated support and/or in the hydrophilic body, and such that constituents of the cell membrane incorporate into the bilayer during or after the bilayer formation. A bilayer produced by the method of the invention, and uses of the bilayer. | 2014-09-04 |
20140249057 | Fluid Processing Device for Oligonucleotide Synthesis and Analysis - The present teachings provide a fluid processing device adapted to produce different oligomers in a plurality of respective reaction sites. The fluid processing device can comprise a first manifold for delivering reactants to the plurality of reaction sites, and a second manifold for removing waste from, and optionally delivering wash fluid to, the plurality of reaction sites. Surface tension control valves can be disposed in fluid communication with the first manifold and can selectively allow reactants and/or fluids into the reaction sites. A method of making oligonucleotides is also provided. | 2014-09-04 |
20140249058 | Ceramic Particles With Controlled Pore And/Or Microsphere Placement And/Or Size And Method Of Making Same - The present invention relates to lightweight high strength microsphere containing ceramic particles having controlled microsphere placement and/or size and microsphere morphology, which produces an improved balance of specific gravity and crush strength such that they can be used in applications such as proppants to prop open subterranean formation fractions. Proppant formulations are further disclosed which use one or more microsphere containing ceramic particles of the present invention. Methods to prop open subterranean formation fractions are further disclosed. In addition, other uses for the microsphere containing ceramic particles of the present invention are further disclosed, as well as methods of making the microsphere containing ceramic particles. | 2014-09-04 |
20140249059 | ASHLESS OR REDUCED ASH QUATERNARY DETERGENTS - A composition of an oil-soluble ionic detergent that does not contribute metal ions to the composition, and which comprises a quaternary non-metallic pnictogen cation and an organic anion having at least one hydrocarbyl group of sufficient length to impart oil solubility to the detergent, the detergent having a total base number (TBN) to total acid number (TAN) ratio of at least 2:1 imparts ash-free basicity to a lubricant composition. | 2014-09-04 |
20140249060 | LUBRICANT COMPOSITION - A lubricating oil composition comprising a lubricating base oil, and a mixture and/or a reaction product of (A) 0.01-0.5% by mass of at least one compound selected from among acid phosphates represented by formula (1) or formula (2), and (B) 0.01-2% by mass of an alkylamine represented by formula (3), based on the total weight of the composition, wherein the acid value due to component (A) is 0.1-1.0 mgKOH/g. [R | 2014-09-04 |
20140249061 | Lubricating Compositions and Methods of Use Thereof - Described are various formulations of lubricant additive composition comprising an additive base oil, a chlorinated paraffin, and a first antioxidant that can be used as a stand-alone lubricant or can be used in an additive package that can be added to another lubricant composition (e.g., an engine oil, a transmission fluid, a turbine oil, a gear oil, a grease, etc.). Also described are various engine oil composition comprising the lubricant additive composition. | 2014-09-04 |
20140249062 | Monoester-Based Lubricants and Methods of Making Same - Disclosed herein are monoester-based lubricant compositions and methods of making these monoester-based lubricant compositions. The monoester lubricant compositions comprise an isomeric mixture of at least one monoester species having a carbon number ranging from C | 2014-09-04 |
20140249063 | Compositions of Hydrocarbon Oils and Oil Soluble PAGS Produced by DMC Catalysts - A lubricant composition comprising a Group I, II, III or IV hydrocarbon oil and a polyalkylene glycol, the polyalkylene glycol having been prepared by reacting a C | 2014-09-04 |
20140249064 | Compositions for Delivering Perfume to the Skin - A body wash composition comprising a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, wherein 80% of the plurality of perfume raw materials comprise a FDV of at least 0.69. | 2014-09-04 |
20140249065 | MICROELECTRONIC SUBSTRATE CLEANING COMPOSITIONS HAVING COPPER/AZOLE POLYMER INHIBITION - Semi-aqueous, alkaline microelectronic cleaning composition of pH≧8 containing:
| 2014-09-04 |
20140249066 | COMPOSITIONS CONTAINING BENEFIT AGENT DELIVERY PARTICLES - The present disclosure relates to benefit agent delivery particles containing at least one benefit agent and at least one cellulosic polymer. The disclosure further relates to compositions containing benefit agent delivery particles and processes for making and using such compositions. The disclosure further relates to methods of imparting a benefit delivery capability to a cleaning composition. | 2014-09-04 |
20140249067 | PREMIX CONTAINING OPTICAL BRIGHTENER - The present disclosure relates to a storage-stable brightener premix composition, which is substantially free of water and comprises an optical brightener, monoethanolamine, and, optionally, a solvent. The present disclosure also relates to methods of making and using the same. | 2014-09-04 |
20140249068 | Concentrated Alkyl Ether Sulfate Amine Salt Compositions - Phase stable, concentrated liquid detergent compositions containing from 21% to 74% by weight of at least one alkyl ether sulfate amine salt anionic surfactant are disclosed. The concentrated liquid detergent compositions also include from 2% to 50% by weight nonionic surfactants and contain less than 50% by weight water. A concentrated surfactant composition containing from 70% to 99% of one or more alkyl ether sulfate amine salts and from 1% to 30% water is also disclosed for use in formulating the concentrated liquid detergent compositions. | 2014-09-04 |
20140249069 | HIGH-EFFICIENCY PERFUME CAPSULES - The present application relates to high efficiency particles and compositions, such as consumer products, comprising such high efficiency particles as well as processes for making and using such high efficiency particles and compositions comprising such high efficiency particles. Such high efficiency particles and compositions provide enhanced benefit agent delivery to a situs that is treated with such high efficiency particles and compositions. | 2014-09-04 |
20140249070 | TREATMENT OF HARD SURFACES - A cleaning composition comprising at least one fatty acid of a sarcosine, and at least one fatty acid of an amino acid, and/or salts thereof. There is also provided an end-use cleaning formulation comprising said cleaning composition having been diluted to 0.2 wt. % to 10 wt. %, and a method of treating a hard surface comprising applying the cleaning composition or the cleaning formulation. The cleaning composition or cleaning formulation are suitable for use in providing soil resistance to a hard surface. | 2014-09-04 |
20140249071 | ENHANCED ANABOLIC CYTOKINE PRODUCTION AND DELIVERY SYSTEM - Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1β, IL-α, IL-6, TNFα, IFNγ and MMPS as these proteins inhibit the healing process. | 2014-09-04 |
20140249072 | COMPLEMENT FACTOR B ANALOGS AND THEIR USES - The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway. | 2014-09-04 |
20140249073 | BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 2014-09-04 |
20140249074 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2014-09-04 |
20140249075 | METHODS FOR REDUCING CD36 EXPRESSION - The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2014-09-04 |
20140249076 | AMYLIN-CALCITONIN CHIMERIC PEPTIDES CONJUGATED TO DURATION ENHANCING MOIETIES - Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis. | 2014-09-04 |
20140249077 | GEL COMPOSITIONS - The present invention is directed to compositions and methods of preparation of phospholipid gels. | 2014-09-04 |
20140249078 | WHEY PROTEIN MICELLES AGAINST MUSCLE ATROPHY AND SARCOPENIA - The present invention relates to whey protein micelles for use in the treatment and/or prevention of a condition linked to a reduced concentration of plasma amino acids in a patient. A further aspect of the invention is a meal replacement comprising whey protein micelles. | 2014-09-04 |
20140249079 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANONIC POLYMER - The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.6 and 7.8, including at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) a hydrophobized anionic polymer. In one embodiment, the compositions according to the invention also includes a prandial insulin. | 2014-09-04 |
20140249080 | Method for the early diagnosis of clinically latent placental insufficiency associated with defective placental maturation - The present invention relates to a method for the early diagnosis of a clinically latent placental insufficiency in pathological placental maturation, and the prophylaxis of an intrauterine fetal hypoxia/asphyxia at the due date or after a prolonged gestation, comprising determining the amount and/or the concentration of the biomarker prokineticin 1 (EG-VEGF) and/or its receptor PKR1 and/or PKR2 in a sample from the pregnant subject and/or the pregnancy. In a preferred embodiment, the invention is based on determining the ratio of the amount and/or the concentration of bFGF/PK1 as a measure of current functional condition and an indicator of latent clinical problems such as placental dysfunction resulting in fetal hypoxia. | 2014-09-04 |
20140249081 | NANOPARTICLE PEPTIDE COMPOSITIONS - The present invention relates to amylin peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of blood glucose regulation. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise glutathione; and at least one amylin peptide that is non-covalently bound to the corona. | 2014-09-04 |
20140249082 | Pharmaceutical Preparation Comprising Recombinant HcG - The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line. | 2014-09-04 |
20140249083 | FORMULATIONS OF GROWTH HORMONE RELEASING FACTOR (GRF) MOLECULES WITH IMPROVED STABILITY - Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a β-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn | 2014-09-04 |
20140249084 | PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS - [Object] To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method. | 2014-09-04 |
20140249085 | CALCITONIN PRODUCTS AND THERAPIES FOR TREATING INFLAMMATORY OR DEGENERATIVE DISEASES - Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject. | 2014-09-04 |
20140249086 | Method for Improving the Stability of Purified Factor VIII After Reconstitution - The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection. | 2014-09-04 |
20140249087 | USE OF HEMOPEXIN TO SEQUESTER HEMOGLOBIN - The invention relates to use of hemopexin (Hx) to sequester extravascular hemoglobin and thereby reduce or prevent inflammation of non-infectious etiology in a subject (e.g., a human). | 2014-09-04 |
20140249088 | METHODS OF TREATING NEUROPATHIC PAIN - The disclosure relates, at least in part, to methods of treating neuropathic pain in a patient in need thereof by administering an effective amount of a disclosed compound, e.g. a peptide NMDA receptor partial agonist. | 2014-09-04 |
20140249089 | METHODS OF TREATING DISEASE WITH RANDOM COPOLYMERS - The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein. | 2014-09-04 |
20140249090 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT BY NASAL ADMINISTRATION OF PATIENTS SUFFERING FROM ANXIETY AND SLEEP DISORDERS - The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide S receptor (NPSR), of the receptor TGR23 and/or of vasopressin receptor-related receptor 1 (VRR1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition. The invention also provides a method for identifying target neurons of a peptide in an animal, wherein the peptide is administered nasally. | 2014-09-04 |
20140249092 | CYCLOSPORIN ANALOG FORMULATIONS - The present disclosure relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations. | 2014-09-04 |
20140249093 | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages - The invention provides a carrier-linked prodrugs, wherein the biologically active moieties comprise at least one carboxylic acid and wherein the linkage between the drug moiety and linker is in the form of an ester wherein the hydroxyl group required for ester formation is provided by the linker moiety and the carboxyl group required for ester formation is provided by the drug moiety. The hydroxyl group of the linker is sterically hindered by the presence of an alkyl or aryl group on the carbon directly bound to or adjacent to the carbon carrying the hydroxyl group (α-carbon). The steric effect of the alkyl or aryl group enables greater control of the rate of hydrolytic degradation of such carrier-linked prodrugs. | 2014-09-04 |
20140249094 | SENSATION-IMPROVING AGENT - An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics. | 2014-09-04 |
20140249095 | Method for Inhibiting Spinocerebellar Ataxia - A method for inhibiting spinocerebellar ataxia is disclosed, which comprises: administering an extract of | 2014-09-04 |
20140249096 | COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES - A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay, is described. | 2014-09-04 |
20140249097 | Inhibition of HIF-1 activation for Anti-Tumor and Anti-Inflammatory responses - The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a cancer cell, tissue or tumor. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a tumor, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods. | 2014-09-04 |
20140249098 | Pharmaceutical Composition Comprising Dapagliflozin and Cyclodextrin - The present invention relates to pharmaceutical compositions comprising dapagliflozin and cyclodextrin, preferably (2-hydroxy)propyl-b-cyclodextrin or γ-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin. | 2014-09-04 |
20140249099 | CANCER THERAPY - The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein. | 2014-09-04 |
20140249100 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS - Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells. | 2014-09-04 |
20140249101 | METHODS FOR TREATING HEPATITIS C VIRUS INFECTION - Disclosed herein is a method of treating a subject infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of sofosbuvir, an effective amount of ribavirin and an effective amount of ledipasvir. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of sofosbuvir, an effective amount of ribavirin and an effective amount of ledipasvir. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. | 2014-09-04 |
20140249102 | Topical Applicator Composition and Process for Treatment of Radiologically Contaminated Dermal Injuries - A topical applicator composition and process are described that decorporate radionuclides from radiologically-contaminated dermal surfaces and that further promote healing. The topical applicator includes a decorporation agent mixed with a plasticizing agent that forms a covering when applied to the dermal surface that decorporates radionuclides and minimizes their systemic migration. The topical applicator formulations can be delivered in conjunction with bandages and other application dressings. | 2014-09-04 |
20140249103 | HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL BACTERIA - Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed. | 2014-09-04 |
20140249104 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE - The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: | 2014-09-04 |
20140249105 | NOVEL CERAMIDE ANALOGUES, PROCESSES FOR PREPARING SAME AND USES THEREOF - Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them. | 2014-09-04 |
20140249106 | Pituitous Silicone Fluids - Fluid compositions are disclosed containing a branched organopolysiloxane and a carrier fluid. The branched organopolysiloxane is obtainable by reacting an organohydrogencyclosiloxane and an alkenyl terminated polydiorganosiloxane. The disclosed fluid compositions possess pituitous rheological properties. | 2014-09-04 |
20140249107 | DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249108 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING MUSCULOSKELETAL PAIN - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249109 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ANKYLOSING SPONDYLITIS - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249110 | TREATMENT OF ARTHRITIS USING DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249111 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING MULTIPLE MYELOMA - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249112 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249113 | COMPOSITIONS FOR ORAL ADMINSTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-09-04 |
20140249114 | BIOCIDAL COMPOSITIONS AND METHODS OF USE - Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and an isothiazolinone compound selected from 1,2-benzisothiazolin-3-one, 2-methyl-1,2-benzisothiazolin-3-one, and mixtures thereof. The compositions are useful for controlling microorganisms in aqueous or water-containing systems. | 2014-09-04 |
20140249115 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS - One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition. | 2014-09-04 |
20140249116 | Acne Solution - A composition for the treatment of acne includes hydrolyzed | 2014-09-04 |
20140249117 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES - The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis. | 2014-09-04 |
20140249118 | TREATMENT OF ORAL LICHEN PLANUS WITH A COMBINATION OF TRIAMCINOLONE AND RETINOIC ACID - Oral lichen planus (OLP) is an immunologic disease which can be controlled and cleared by topical application of a composition of triamcinolone acetonide 0.1% and retinoic acid 0.05% in Orabase® on the affected areas of the mucosa, thrice daily for three weeks. The combined therapy is more effective than triamcinolone acetonide alone in Orabase®. By this method, clearance can be maintained by less frequent application or lower concentrations of the composition. | 2014-09-04 |